This patent presents a groundbreaking solution to assess blood clotting and bleeding tendencies with high precision, targeting a critical gap in medical diagnostics. Current blood clotting tests, like TEG and ROTEM, fail to mimic real-life conditions where platelets interact with vessel walls. These tests often require large blood samples, lack accuracy for predicting bleeding or clotting risks, and are unsuitable for precision medicine or paediatric use.
Core Features
The invention uses a tiny blood sample (as little as 5 microliters) placed on a glass matrix. Coloured indicators bind to platelets, visually capturing their behaviour during clotting. Advanced imaging technology and AI analyse these visual changes, assessing platelet function and categorizing bleeding or clotting risks.
Inventive Step
Unlike existing methods, this technology directly observes platelets under near-physiological conditions. By analysing platelet transformations using AI-powered imaging, it can predict outcomes more accurately than suspension-based tests. This innovative use of fluorescent markers and machine learning represents a significant leap in diagnostic precision.
Benefits
- Accuracy: Reliable prediction of bleeding and clotting risks for surgeries and treatments.
- Minimal Sample Requirement: Suitable for paediatric and vulnerable patients.
- Speed: Results within 15-50 minutes.
- Precision Medicine: Personalized treatment recommendations for conditions like thrombosis, preeclampsia, and COVID-19 complications.
Broader Impact
This technology promises to revolutionize healthcare by enabling safer surgeries, better management of clotting disorders, and reducing complications in vulnerable groups like children and pregnant women. It enhances precision medicine, addressing critical challenges in modern healthcare.
This invention not only solves unmet clinical needs but also sets a new standard for blood diagnostics, benefiting patients and healthcare systems globally.